Drug Trial Radar · NCT04669808
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Dec 28, 2020
Primary completion
Feb 9, 2023
Study completion Feb 9, 2023
Sponsor
- Lead sponsor
- SirnaomicsIndustry
- Sponsor type
- Industry
- Collaborators
- Amarex Clinical Research
- First posted
- Dec 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC). Goals: * To determine the safe and effective recommended dose of STP705 for the treatment of basal cell carcinoma. * Analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2.
Conditions
- Basal Cell Carcinoma
Interventions
STP705Drug
Dry powder for intra-and peri-lesional injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With Histological Clearance of Treated Basal Cell Carcinoma Lesion at the End of Treatment (EOT)Time frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Clinical and Cosmetic Research
Aventura, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.